The proteomic revolution

Published on September 27, 2012 Updated on May 29, 2022   55 min

A selection of talks on Oncology

Today I'm going to tell you about the proteomic revolution. As it says on slide 1, my name is Larry Gold, the CEO and Chairman of the Board of SomaLogic company in Boulder, Colorado. I'm also a part-time faculty member at the University of Colorado in Boulder, where I've been on the faculty since 1970. Let's just jump into the proteomic revolution.
For the next few slides, I'm going to try to put into context proteomics (the topic for today's talk), in the context of other '-omices'. I'll start by showing a way of thinking about what happened when the human genome was sequenced. Of course it's still being sequenced, but what has happened is that everyone is excited that with that genome sequence we'll able to understand medicine, and health, and wellness, and aging. A lot of unbelievable things. In a way that's true. In a way, having the genotype may be equivalent to having anatomy 200 years ago. There's this notion that knowledge of something as basic as the genome will be useful, and it is and has been, and will continue to be. What I want to talk about is the difference between knowing the genotype (which is really a lot about the ensuing 100 years of your life), and these other kinds of things that have more to do with phenotype. Slide number 3 is exactly like slide number 2, except there's a black box in the middle.